Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 996,956
  • Shares Outstanding, K 65,118
  • Annual Sales, $ 75,620 K
  • Annual Income, $ -72,700 K
  • EBIT $ 9 M
  • EBITDA $ 17 M
  • 60-Month Beta 1.60
  • Price/Sales 6.98
  • Price/Cash Flow N/A
  • Price/Book 3.94

Options Overview Details

View History
  • Implied Volatility 117.15% (+6.45%)
  • Historical Volatility 79.27%
  • IV Percentile 43%
  • IV Rank 12.52%
  • IV High 421.76% on 04/04/25
  • IV Low 73.56% on 06/10/25
  • Expected Move (DTE 12) 1.70 (11.10%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 83
  • Volume Avg (30-Day) 115
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 7,821
  • Open Int (30-Day) 7,367
  • Expected Range 13.61 to 17.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.41
  • Low Estimate -0.51
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -295.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.64 +4.58%
on 12/18/25
19.17 -20.14%
on 12/17/25
-0.10 (-0.65%)
since 12/02/25
3-Month
7.24 +111.61%
on 10/07/25
19.17 -20.14%
on 12/17/25
+7.68 (+100.66%)
since 10/02/25
52-Week
3.50 +337.43%
on 04/07/25
19.17 -20.14%
on 12/17/25
+8.20 (+115.33%)
since 01/02/25

Most Recent Stories

More News
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics: Q3 Earnings Snapshot

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model  Data...

GLUE : 15.31 (-2.36%)
Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

GLUE : 15.31 (-2.36%)
SDZNY : 73.0000 (+0.31%)
NVS : 138.54 (+0.49%)
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s  growing preclinical immunology...

GLUE : 15.31 (-2.36%)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...

GLUE : 15.31 (-2.36%)

Business Summary

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 16.34
2nd Resistance Point 16.08
1st Resistance Point 15.69
Last Price 15.31
1st Support Level 15.05
2nd Support Level 14.79
3rd Support Level 14.41

See More

52-Week High 19.17
Last Price 15.31
Fibonacci 61.8% 13.18
Fibonacci 50% 11.34
Fibonacci 38.2% 9.49
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar